Wichita Urology Group | Wichita, KS

Research site

(Unclaimed)

Location

2626 N Webb Road, Wichita, Kansas, United States of America

Site insights

Top conditions

Top treatments

TAR-200

UGN-102

Androgen

MK-3475-905

TAR-210

Enfortumab

Vibegron

Cisplatin

Gemcitabine

Leuprolide Acetate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 18 total trials

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

This Phase 3, multinational, single-arm, multicenter study will evaluate the efficacy and safety of UGN-102 as primary chemoablative therapy in patie...

Active, not recruiting

Bladder Cancer

Urothelial Carcinoma

Drug: UGN-102

A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

Prostate cancer is usually treated by reducing the amount of testosterone in the body. PRL-02 depot is a potential treatment for men with advanced pr...

Enrolling

Metastatic Castration Resistant Prostate Cancer

Metastatic Castration-sensitive Prostate Cancer

Drug: prednisone

Drug: PRL-02 injection

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

This is a Phase 3, open-label, randomized trial designed to evaluate the RFS of TURBT followed by cretostimogene grenadenorepvec versus TURBT followe...

Enrolling

Bladder Cancer

Urologic Cancer

Other: n-dodecyl-B-D-maltoside

Drug: Cretostimogene Grenadenorepvec

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Enrolling

Bladder Cancer

Biological: Cetrelimab

Drug: TAR-200

A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guérin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy (SunRISe-1)

The purpose of this study is to evaluate the overall complete response (CR) rate in participants treated with TAR-200 in combination with cetrelimab...

Active, not recruiting

Urinary Bladder Neoplasms

Drug: TAR-200

Biological: Cetrelimab

Locations recently updated

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) (SunRISe-5)

The purpose of this study is to compare disease free survival (DFS) in participants with recurrence of papillary-only high-risk non-muscle-invasive b...

Enrolling

Non-Muscle Invasive Bladder Neoplasms

Drug: Mitomycin C

Drug: Gemcitabine

A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC (KANGUROO)

The purpose of this study is to evaluate the safety, efficacy, and PK of vibegron in pediatric participants with NDO who are regularly using CIC

Enrolling

Neurogenic Detrusor Overactivity

Drug: Vibegron

Locations recently updated

A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer (MoonRISe-1)

The main purpose of this study is to compare the disease-free survival between participants receiving treatment with TAR-210 versus investigator's ch...

Enrolling

Non-Muscle Invasive Bladder Cancer

Drug: Gemcitabine

Drug: MMC

Acoustic Enhancer Research on Laser Lithotripsy (AEROLITH)

A pivotal study to evaluate the safety and effectiveness of Applaud Acoustic Enhancer when used in conjunction with conventional ureteroscopic laser...

Active, not recruiting

Urinary Stones

Device: Ureteroscopy Laser Lithotripsy (URS-LL) with Acoustic Enhancer

Device: Standard Ureteroscopic Laser Lithotripsy

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the i...

Enrolling

High-risk Non-muscle Invasive Bladder Cancer

Biological: Pembrolizumab

Biological: BCG

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

This is a study of perioperative pembrolizumab or enfortumab vedotin in combination with pembrolizumab in participants who are cisplatin-ineligible o...

Active, not recruiting

Urinary Bladder Cancer, Muscle-invasive

Procedure: Surgery (radical cystectomy (RC) plus Pelvic Lymph Node Dissection [PLND])

Drug: Pembrolizumab

Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate

This was a randomized study to evaluate the risk of major adverse cardiovascular events (MACE) for relugolix compared with leuprolide acetate. Enroll...

Active, not recruiting

Prostate Cancer

Drug: Leuprolide Acetate

Drug: Relugolix